MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15176869

Медицинская библиотека · Journal of clinical medicine · 2026

Prognostic Value of the Lung Immune Prognostic Index and an ECOG-Albumin-LIPI Nomogram in Metastatic NSCLC Patients Treated with Second- or Third-Line Nivolumab.

Divriklioğlu Didem, Bayrakçı İsmail, Bakır Kahveci Gizem, Gökmen İvo, Koç Dicle Yurdatap, Demirdelen Ece, Küçükarda Ahmet, Hacıoğlu Muhammet Bekir, Erdoğan Bülent, Topaloğlu Sernaz

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

Clinical outcomes with immune checkpoint inhibitors (ICIs), such as nivolumab, vary among patients with metastatic non-small cell lung cancer (NSCLC). The Lung Immune Prognostic Index (LIPI) may help stratify prognosis. This study evaluated the prognostic significance of LIPI in patients receiving second- or third-line nivolumab and developed a nomogram for individualized survival estimation.

Methods

This single-center retrospective study included 142 patients with metastatic NSCLC who received second- or third-line nivolumab between February 2022 and December 2024, after progression on platinum-based chemotherapy. LIPI was calculated from baseline values obtained within 14 days before nivolumab initiation, based on a derived neutrophil-to-lymphocyte ratio (dNLR) > 3 and lactate dehydrogenase (LDH) > 225 U/L (institutional upper limit of normal), classifying patients as good-, intermediate-, or poor-risk (0, 1, or 2 factors, respectively). Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method; independent prognostic factors were assessed by multivariable Cox regression, and a prognostic nomogram combining ECOG performance status, serum albumin, and LIPI was developed and internally validated.

Results

By LIPI, 34.5%, 45.1%, and 20.4% of patients were at good, intermediate, and poor risk, respectively. Objective response and disease control rates were 29.6% and 55.6%. Median OS and PFS were 19.3/8.0/3.1 and 8.6/3.1/2.5 months across good, intermediate, and poor LIPI groups (log-rank p < 0.001). In multivariable analysis, ECOG 2 (hazard ratio [HR], 4.94), albumin per 1 g/dL (HR 0.27), and poor versus good LIPI (HR 3.74) were independently associated with OS. A nomogram combining these three factors showed acceptable discrimination (optimism-corrected Harrell C-statistic 0.742).

Conclusions

LIPI was independently associated with prognosis in this cohort. Combining LIPI with ECOG and albumin may aid individualized risk assessment, pending external validation.

Для цитирования: Divriklioğlu Didem, Bayrakçı İsmail, Bakır Kahveci Gizem, Gökmen İvo, Koç Dicle Yurdatap, Demirdelen Ece, Küçükarda Ahmet, Hacıoğlu Muhammet Bekir, Erdoğan Bülent, Topaloğlu Sernaz. Prognostic Value of the Lung Immune Prognostic Index and an ECOG-Albumin-LIPI Nomogram in Metastatic NSCLC Patients Treated with Second- or Third-Line Nivolumab.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15176869.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.